Year: 2024

Hosted by Veteran Crime Author Sara James McLaughlin Launch Expands PodcastOne’s Original IP Slate For Television and Film Adaption Total Downloads for Opportunist Top 5.5 Million, Total Episodes 94 LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) — PodcastOne (NASDAQ: PODC), a leading podcast platform and a subsidiary of LiveOne (NASDAQ: LVO), is excited to announce the release of the latest season of its hit series, The Opportunist, hosted by veteran true crime author and podcast host Sara James McLaughlin. In this new season, Tim Ballard: Unmasking a Hero delves into the dramatic rise and fall of Tim Ballard, the embattled founder of Operation Underground Railroad. Known for his work rescuing trafficked children, Ballard’s public persona hides darker allegations. In this season, McLaughlin takes listeners on a gripping investigative...

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience’s Biopharma Solutions business unit. “This transaction further solidifies XOMA Royalty’s unique position in the biotech royalty space. We believe a growing base of commercial revenues coupled with a large...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each year and more than 29,000 patients die in the U.S. from C. diff. annually. Rates of recurrent C. diff. have increased significantly in recent years, representing a major public health challenge.SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 2 clinical trial...

DZS among five NTIA certified compliant U.S. telecom electronics equipment manufacturers, offers a wide range of future-ready fiber access solutionsDZS and manufacturing partner Fabrinet are building BEAD-ready fiber optic equipment in the U.S. today DZS has an extensive portfolio of fiber access, optical transport and cloud-software solutions that provide end-to-end support for BEAD deployments DZS has decades-long U.S. manufacturing history featuring proven, environmentally hardened solutions ideally suited for rural and unserved areasDALLAS, Oct. 22, 2024 (GLOBE NEWSWIRE) — DZS (OTC: DZSI), a global leader of Networking, Connectivity and Cloud Edge software solutions enabling broadband everywhere, today announced that the company’s U.S. manufactured electronic components have been certified as compliant with the domestic...

RISHON LE ZION, Israel, Oct. 22, 2024 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC), an integrator of supply chain technologies, announced today that its Supply Chain Division, which provides franchised distribution of electronic components, received a $500,000 order from a customer in India. The order is for delivery gradually by August 2025. Avidan Zelicovski, BOS’ President, expressed confidence in the division’s ability to expand its global sales, citing the success of achieving $6 million in overseas sales in 2023. Additionally, he highlighted that since the announcement on July 10, 2024, regarding initial sales to Greek customers, the division has received $280,000 orders from that territory. About BOS Through its three business divisions, BOS...

Rebranded and new state-of-the-art website which aligns our real estate syndication software with Janover’s comprehensive suite of commercial real estate solutions Boca Raton, FL, Oct. 22, 2024 (GLOBE NEWSWIRE) — Janover Inc. (Nasdaq: JNVR) (“Janover” or the “Company”), an AI-enabled platform for commercial real estate transactions, today announced the rebranding of its real estate syndication software, Groundbreaker, to Janover Connect. This strategic move includes the launch of a new, state-of-the-art website designed to better communicate the platform’s value proposition and align it more closely with Janover’s suite of comprehensive commercial real estate solutions while showcasing Janover Engage, its new marketplace matching real estate syndicators and accredited investors. The new...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) — Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12, 2024 before the market opens. The company will hold a conference call at 8:00 am Eastern Time to discuss the results. The call will be hosted by Rob Wiesenthal, Blade’s Chief Executive Officer, and Will Heyburn, Blade’s Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will be provided to join the call. An audio-only webcast of the call may be accessed from the Investors section of the Company’s website at https://ir.blade.com/ or by registering at the link here. A replay of the webcast...

MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The event will be held from October 29 to November 1, 2024, in Madrid, Spain. Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present the following posters: Poster LP023 Title: Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer’s Patients. Date: Tuesday, October 29, 3:00 PM – Wednesday, October 30, 5:00 PM (CET). Poster LP074 Title: Biomarker Data Showed Buntanetap Reduced...

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here. The event will feature comments from Luke J. Laffin, MD (Cleveland Clinic), James M. Luther, MD, MSCI (Vanderbilt University Medical Center), and Rhian Touyz, MBBCh, MSc (Med), PhD (McGill University Health Centre) who will each discuss the unmet medical need in uncontrolled and resistant hypertension and the potential for lorundrostat, a development stage, highly selective...

– Expects Total Revenue Between $26.0 and $28.0 Million; Grows 23-33% Year-over-Year – – Expects GAAP Net Income / (Loss) Between ($6.0) and ($6.75) Million Due to Non-Cash Increase in Warrant Liability of Between $8.0 and $9.0 Million – – Expects Adjusted EBITDA Between $14.0 and $16.0 Million; Grows 30-48% Year-over-Year – – Third Quarter 2024 Earnings Release and Conference Call to be Held Thursday, November 7, 2024 – ORLANDO, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) — Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced preliminary unaudited financial results for the third quarter ended September 30, 2024. Preliminary Financial Results – Third Quarter 2024 Based upon...